ENHANCEMENT OF SOLUBILITY OF TADALAFIL BY COCRYSTAL APPROACH by V. Vinesha et al.
V. Vinesha et al. Int. Res. J. Pharm. 2013, 4 (4) 
Page 218 
  INTERNATIONAL RESEARCH JOURNAL OF PHARMACY 
www.irjponline.com  ISSN 2230 – 8407 
  Research Article 
   
ENHANCEMENT OF SOLUBILITY OF TADALAFIL BY COCRYSTAL APPROACH 
V. Vinesha*, M. Sevukarajan, R. Rajalakshmi, G. Thulasi Chowdary, K. Haritha 
Sree Vidyanikethan College of Pharmacy, Tirupati, Chittoor (Dt.), Andhra Pradesh, India 
Email: Vinesha248@gmail.com 
 
Article Received on: 16/02/13 Revised on: 03/03/13 Approved for publication: 11/04/13 
 
DOI: 10.7897/2230-8407.04444 
IRJP is an official publication of Moksha Publishing House. Website:  www.mokshaph.com 
© All rights reserved.  
 
ABSTRACT 
Cocrystallization is an emerging method to optimize physicochemical properties of pharmaceutically active compounds including dissolution rate and stability. 
The main aim of this study was to increase the solubility by cocrystal approach and characterize the cocrystals (1:1) involving tadalafil and salicylic acid 
which were prepared by solvent evaporation method (crystal form I), neat grinding method (crystal form II), co-grinding method (crystal form III). The 
prepared cocrystals were characterized by X-Ray Diffraction studies, Fourier Transfoorm Infrared Spectrophotometry, microscopic studies, solubility and 
dissolution studies. The prepared cocrystals showed increased solubility than the pure drug. 
Key words: Cocrystals, Tadalafil, Salicylic acid, Solubility. 
 
INTRODUCTION 
Therapeutic  effectiveness  of  a  drug  depends  upon  the 
bioavailability  and  ultimately  upon  the  solubility  of  drug 
molecules.  Solubility  is  one  of  the  important  parameter  to 
achieve desired concentration of drug in systemic circulation 
for pharmacological response to be shown
1-3. Though there 
are  so  many  techniques  to  improve  the  solubility, 
Cocrystallization  is  one  of  the  new  approaches
4.  These 
cocrystals include  molecular complexes, solvates, inclusion 
complexes, channel compounds, clathrates. 
Cocrystals are discrete neutral molecular reactants which are 
structurally  crystalline  materials  containing  two  or  more 
components  present  in  definite  stoichiometric  amounts. 
Pharmaceutical  cocrystals  contain  an  active  pharmaceutical 
ingredient (API) and a co former which may/may not have 
pharmacological  activity
5-9.  Co  former  generally  forms 
hydrogen bond with the API. Both the API and co  former 
should  contain  either  hydrogen  donor  or  accepting  groups 
like ether, thioether, alcohol, ketone, thioketone, nitrate ester, 
phosphate ester, ester, thioester, sulfate ester, carboxylic acid, 
phosphonic  acid,  sulfonic  acid,  amide,  primary  amine, 
secondary  amine,  ammonia,  thiocyanate,  cyanamide, 
thiocyanate,  oxime,  nitrile  diazo,  organohalide,  pyrrole, 
thiophene,  furan,  pyridine,  imidazole,  indole,  pyrrolidone, 
epoxide, phenol, sulfone, mercapto and methyl thio, hydroxyl 
groups etc. 
The  other  forces  involved  in  formation  of  cocrystals  are 
vander  waals  forces,  P-P  interactions,  stacking  interactions 
and halogen  bonding
10-13.  This crystal engineering involves 
the modification of crystal packing of solids by changing the 
intermolecular interactions. These cocrystals can be prepared 
by  solution  method,  reaction  crystallization,  cooling 
crystallization, grinding method, anti solvent method etc
14-20.  
The  selection  of  coformer  depends  on  the  formation  of 
hydrogen  bonding  capacity.  In  this  research  work  salicylic 
acid was selected as it is having hydroxyl and carboxylic acid 
groups to form the hydrogen bond with the API. 
The  work  presented  here  involves  the  investigation  of 
cocrystals  of  Tadalafil  (TDF),  a  cyclic  guanosine 
monophosphate (cGMP) specific Type V phosphodiesterase 
(PDE5)  inhibitor  used  to  treat  erectile  dysfunction,  with 
salicylic  acid  (SA)  to  enhance  the  solubility  for  better 
therapeutic  activity
21-23.  The  supramolecular  synthons  are 
generally  prepared  by  slow  evaporation  from  a  solution 
containing stiochimetric amounts of individual components. 
These cocrystals also improve the physicochemical properties 
without altering the pharmacological activity
24-28. 
 
MATERIALS AND METHODS 
Tadalafil  obtained  as  gift  sample  from  Matrix  Pvt.  Ltd., 
Hyderabad.  Salicylic  acid  from  S.D.Fine  Chem.  Ltd., 
Mumbai,  Acetonitrile  from  Merck  Pvt.  Ltd.,  Mumbai  and 
remaining materials used were of analytical grade. TDF and 
SA cocrystals were prepared by solvent evaporation method, 
neat grinding method and co-grinding method by taking each 
component  in  1:1  molar  ratio  by  different  experimental 
approaches.  
 
Evaluation Studies 
The prepared cocrystals were evaluated for percentage yield, 
flow  properties  like  angle  of  repose  and  following 
parameters. 
 
Drug content 
For  the  determination  of  drug  content,  prepared  cocrystals 
(5mg) were weighed and dissolved in 10ml of methanol and 
the solutions were analysed spectrophotometrically at 284nm, 
after sufficient dilution with methanol
29.  
 
Determination of solubility 
Saturation solubility studies of Tadalafil were performed. In 
this study, an excess quantity of drug was placed in test tube 
containing  10ml  of  different  media  (0.1N  HCl  with  0.5% 
SLS  solution,  pH  6.8  Phosphate  buffer  with  0.5%  SLS 
solution,  0.5%  SLS  solution).  These  were  agitated  in 
mechanical  shaker  for  24hrs  at  room  temperature.  The 
solution was filtered and the amount of the drug dissolved 
was analysed spectrophotometrically at 284nm
30.    
 
Fourier-Transform Infrared Spectroscopy (FTIR) 
The compatibility of TDF with the SA was checked by FTIR. 
The  infrared  spectra  of  the  crystals  in  KBr  pellets  were 
recorded from 400 – 4000 cm
-1 at room temperature
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Page 219 
Table 1: Preformulation studies 
 
Formulation  %Yield  Angle Of Repose 
TDF  -  20.12
0± 0.25
0 
Crystal form I  66.17  21.54
0± 0.73
0 
Crystal form II  78.38  21.56
0± 0.43
0 
Crystal form III  98.97  19.91
0± 0.57
0 
 
Table 2: Drug content in methanol 
 
Formulation  % Drug Content 
TDF  - 
Crystal form I  82.8 
Crystal form II  76.6 
Crystal form III  24.8 
 
Table 3: Solubility studies 
 
Formulation  0.1 N HCl with 0.5% SLS solution 
(mg/ml) 
6.8 phosphate  buffer with 0.5% SLS 
solution (mg/ml) 
0.5% SLS solution 
(mg/ml) 
TDF  1.55 ± 0.5  0.1± 0.1  0.41± 0.6 
Crystal form I  0.26 ± 0.1  0.08± 0.1  0.50± 0.8 
Crystal form II  1.77 ± 0.6  1.045± 0.2  1.50± 0.5 
Crystal form III  2.8 ± 0.15  1.19± 0.09  1.4 ± 0.2 
 
Table 4: Drug release studies in 0.5% SLS solution 
 
Time (min)  % Drug release 
TDF  Crystal form I  Crystal form II  Crystal form III 
0  0  0  0  0 
5  38.76± 0.23  10.44± 0.21  46.34± 0.5  42.9± 0.29 
15  55.46± 0.51  11.66± 0.60  59.45± 0.37  48.18± 0.65 
30  65.23± 0.36  17.91± 0.52  72.48± 0.49  57.74± 0.52 
45  74.76± 0.25  14.81± 0.29  76.95± 0.62  57.41± 0.26 
60  82.91± 0.49  18.07± 0.38  84.69± 0.38  63.26± 0.43 
90  83.1± 0.19  26.6± 0.43  89.25± 0.71  72.45± 0.59 
 
 
Table 5: Drug release studies in 0.1 N HCl with 0.5% SLS solution 
 
Time(min)  % Drug release 
TDF  Crystal form I  Crystal form II  Crystal form III 
0  0  0  0  0 
5  36.17 ± 0.37  7.97 ± 0.63  38.95 ± 0.39  37.72 ± 0.28 
15  59.07 ± 0.28  9.18 ± 0.51  59 ± 0.28  47.72 ± 0.53 
30  64.42 ± 0.53  9.58 ± 0.60  74.81 ± 0.69  59.69 ± 0.38 
45  68.59 ± 0.31  12.1 ± 0.43  80.92 ± 0.71  71.49 ± 0.48 
60  78.87 ± 0.49  14.53 ± 0.29  84.63 ± 0.52  70.49 ± 0.52 
90  80.88 ± 0.20  17.85 ± 0.17  86.23 ± 0.56  88.1 ± 0.35 
 
Table 6: Drug release studies in pH 6.8 phosphate buffer with 0.5% SLS solution 
 
Time (min)  % drug release 
TDF  Crystal form I  Crystal form II  Crystal form III 
0  0  0  0  0 
5  22.98 ± 0.57  8.03 ± 0.45  22.07 ± 0.67  22.28 ± 0.52 
15  29.22 ± 0.48  13.5 ± 0.67  31.2± 0.58  30.25 ± 0.65 
30  44.3 ± 0.39  17.81 ± 0.63  46.86 ± 0.65  45.25 ± 0.67 
45  50.27 ± 0.28  23.47 ± 0.51  56.38 ± 0.46  55.36 ± 0.98 
60  60.59 ± 0.26  25.66 ± 0.27  68.36 ± 0.56  69.53 ± 0.87 
90  75.41 ± 0.38  33.25 ± 0.37  78.32 ± 0.95  81.41 ± 0..64 
 
Table 7: Release Parameters of Pure Drug and prepared crystal forms in 0.5% SLS solution 
 
Release kinetics  Zero order kinetics  First order kinetics  Higuchi model  Krosmeyer Peppas model  Hixson Crowell model 
TDF  R
2  0.7357  0.7357  0.9378  0.9956  0.8785 
m  0.8131  -0.8131  9.0597  0.2911  -0.0036 
C  29.57  70.428  12.051  1.3909  4.557 
 
Crystal form 
I 
R
2  0.7978  0.7978  0.8971  0.7996  0.8785 
m  0.2265  -0.2265  2.3702  0.2879  -0.0036 
c  6.2856  93.714  2.1832  0.7791  4.557 
 
Crystal form 
II 
R
2  0.658  0.658  0.8888  0.9942  0.8785 
m  0.7705  -0.7705  8.8368  0.2331  -0.0036 
c  34.342  65.658  16.459  1.5046  4.557 
 
Crystal form 
III 
R
2  0.6164  0.6164  0.8393  0.9456  0.8785 
m  0.5716  -0.5716  6.582  0.1737  -0.0036 
c  28.843  71.157  15.443  1.4966  4.557 
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Table 8: Release Parameters of Pure Drug and prepared crystal forms in 0.1N HCl with 0.5% SLS solution 
 
Releases kinetics  Zero order kinetics  First order kinetics  Higuchi model  Krosmeyer peppas model  Hixson crowell model 
 
TDF 
R
2  0.66  0.66  0.8902  0.9433  0.8785 
m  0.7171  -0.7171  8.2181  0.2716  -0.0036 
c  30.332  69.668  13.719  1.4011  4.557 
 
Crystal 
form I 
R
2  0.8221  0.8221  0.9336  0.8412  0.8785 
m  0.158  -0.158  1.6617  0.267  -0.0036 
c  4.6429  95.357  1.7692  0.6682  4.557 
 
Crystal 
form II 
R
2  0.6231  0.6237  0.8681  0.9199  0.8785 
m  0.8008  -0.8008  0.8008  0.2955  -0.0036 
c  34.049  65.951  14.733  14.125  4.557 
 
Crystal 
form III 
R
2  0.7745  0.7745  0.947  0.9751  0.8785 
m  0.7847  -0.7847  8.5628  0.2893  -0.0036 
c  26.191  73.809  10.195  1.3588  4.557 
 
Table 9: Release Parameters of Pure Drug and prepared crystal forms in 6.8 phosphate buffer with 0.5% SLS solution 
 
Release kinetics  Zero order kinetics  First order kinetics  Higuchi model  Korsmeyer peppas model  Hixson crowell Model 
 
TDF 
R
2  0.9093  0.9093  0.991  0.9678  0.8785 
m  0.7412  -0.7412  7.6367  0.4182  -0.0036 
c  14.453  85.547  1.6372  1.03  4.557 
 
crystal 
form I 
R
2  0.9227  0.9227  0.9965  0.9954  0.8785 
m  0.3341  -0.3341  3.4267  0.4846  -0.0036 
c  5.6941  94.306  -0.0028  0.5588  4.557 
 
crystal 
form II 
R
2  0.9011  0.9011  0.995  0.986  0.8785 
m  0.8032  -0.8032  8.3292  0.4572  -0.0036 
c  15.202  84.798  1.0396  0.9989  4.557 
 
Crystal 
form III 
R
2  0.9228  0.9228  0.9925  0.9758  0.8785 
m  0.8365  -0.8365  8.5609  0.4664  -0.0036 
c  14.164  85.836  -0.0094  0.9842  4.557 
 
 
 
Figure 1: IR spectrum of TDF, SA, Crystal form I, Crystal form II and Crystal form III 
 
 
 
Figure 2: Microscopic studies of TDF, SA, Crystal form I, Crystal form II and Crystal from III 
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Figure 3: XRD pattern of TDF, Crystal form I, Crystal form II and Crystal form III 
 
 
 
Figure 4: Drug release profiles of TDF and crystal forms: (a) In 0.5% SLS solution       
(b) In 0.1 N HCl with 0.5% SLS solution (c) In pH 6.8 Phosphate buffer with 0.5% SLS solution 
 
 
X-Ray powder diffraction (XRD) 
The  XRD  were  undertaken  to  investigate  the  crystalline 
nature of Tadalafil, Salicylic acid and prepared crystal forms. 
The study was carried out by X-Ray Diffractometer using Cu 
kα radiation. The tube operated at 45 kV, 9mA and data was 
collected over an angular range from 2θ diffraction angle of 0 
to 500 in continuous scan mode using a step size of 0.050 and 
a time of 0.1S
32. 
 
Dissolution studies 
The dissolution of co-crystals was studied using USP Type II 
dissolution  apparatus  containing  900ml  dissolution  media 
(0.5% SLS solution, 0.1N HCl with 0.5% SLS solution, 6.8 V. Vinesha et al. Int. Res. J. Pharm. 2013, 4 (4) 
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phosphate  buffer  with  0.5%  SLS  solution)  maintained  at 
37±0.5
0C  and  stirred  at  50  rpm.  Samples  were  withdrawn 
periodically  and replaced with a  fresh dissolution  medium. 
These samples were analysed for the drug release with the 
help of UV spectrophotometer at wavelength of 284nm
 34-36. 
Further  the  in-vitro  drug  release  kinetics  like  zero  order 
(cumulative percent release against time), Higuchi equation 
(cumulative percent release against square root of time), first 
order  model  (log  cumulative  percent  release  against  time), 
krosmeyer’s  peppas  model  (log  cumulative  percent  release 
against log time) and Hixson crowell model (cubth root of 
percent drug remained against time) were studied
33. 
 
RESULTS AND DISCUSSION 
Different types of TDF-SA cocrystals (1:1) were prepared. In 
solvent  evaporation  technique  both  the  ingredients  were 
dissolved in Acetonitrile and evaporated to obtain the crystal 
form I. In  neat grinding method both the ingredients were 
ground in mortar-pestle for 30 min using a small amount of 
solvent  acetonitrile  to  obtain  crystal  form  II  and  in  co-
grinding method both the ingredients were ground in mortar-
pestle for 30min without any addition of solvent to  obtain 
crystal form III.  
The  percentage  yield  and  angle  of  repose  of  the  prepared 
cocrystals  were  shown  in  Table  1.  Drug  content  of  the 
prepared cocrystals was measured in methanol and the results 
were shown in Table 2. From the solubility studies (table no-
3) it was noted that the crystal form I has less solubility than 
other crystal forms in all buffer solutions. 
The incompatibility and formation of cocrystals were carried 
out by infrared spectroscopy from 400 to 4000 cm
-1 for the 
pure TDF and three crystal forms using KBr pellets. As there 
were  minor  changes  in  the  peaks,  indicates  that  cocrystals 
were formed. From the literature survey it was found that the 
formation  of  cocrystals  was  due  to  formation  of  hydrogen 
bonds between the TDF and SA (Figure 1). 
The differences in some  peak regions, shift in N-H stretch 
(3318.90cm
-1),  C-H  stretch  (2897cm
-1),  amino  group 
(1642.46  cm
-1),  tertiary  amine  C-N  stretch  (1146.91  cm
-1), 
absence  of  some  peaks like aromatic C-H stretch (3019.62 
cm
-1) and C=O stretch (1730.95 cm
-1) were observed. 
From the microscopic studies the shape of the crystal form 
was  identified  and  they  were  shown  in  Figure  2.  The 
cocrystal formation (H-bonding) between TDF and SA was 
confirmed by X-ray diffraction studies, as there were changes 
in characteristic peak (100% peak) for the crystal forms from 
the pure TDF (Figure 3). 
Drug  release  from  different  prepared  cocrystal  forms  (I,  II 
and III) was studied using 0.5% SLS solution (Table 4), 0.1N 
HCl  with  0.5%  SLS  solution  (Table  5),  pH  6.8  phosphate 
buffer  with  0.5%  SLS  solution  (Table  6).  Among  the 
formulations, crystal form II and crystal form III have high 
solubility than  crystal form  I (Figure 4).  It was  found that 
crystal form II showed more solubility in 0.5% SLS solution 
and crystal form III showed more solubility in 0.1N HCl and 
6.8 phosphate buffer. Crystal form I showed less solubility 
compared to other crystal forms. 
From the release kinetics it was observed that the pure TDF 
follows krosmeyer peppas model, and crystal form I follows 
higuchi  model  in  all  buffers,  crystal  form  II  follows 
krosmeyer  peppas  model  in  0.5%  SLS  solution,  0.1N  HCl 
with 0.5% SLS solution, and higuchi  model 6.8 phosphate 
buffer  with  0.5%  SLS  solution,  crystal  form  III  follows 
krosmeyer  peppas  model  in  0.5%  SLS  solution,  0.1N  HCl 
with 0.5% SLS solution, and higuchi  model 6.8 phosphate 
buffer  with  0.5%  SLS  solution.  The  results  were  given  in 
Tables 7-9. 
 
CONCLUSION 
From the above research work, it can be concluded that the 
proper selection of  coformer is  very important to form the 
cocrystals.    A  TDF-  SA  (1:1)  cocrystal  was  successfully 
prepared by three methods: solvent evaporation method, neat 
grinding method and co-grinding method using acetonitrile as 
solvent. A new species of cocrystals between TDF and SA 
was due to hydrogen bond formation, confirmed by FTIR and 
XRD studies as it showed changes in the characteristic peaks. 
The TDF-SA cocrystal is of considerable interest because it 
offers potential to improve the TDF solubility. Finally from 
the dissolution studies, it was concluded that the solubility 
was  increased  in  neat  grinding  method  and  co-grinding 
method rather by solvent evaporation method. 
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